This study analyzes real-world FAERS data on neurotoxicity and rare adverse events in BCMA-directed #CART therapy. Cilta-cel and ide-cel show distinct neurotoxic profiles, with significant safety signals detected. Ongoing monitoring remains essential.

Dr. Steven M. Devine’s ‘Reflections’ article explores the generosity of unrelated stem cell donors and the evolution of transplant accessibility. From the founding of NMDP to innovations in MMUD transplants, progress continues toward equitable care.

The February issue of 'Transplantation and Cellular Therapy,' is now available online: @ELShematology

Dr. Rebecca Gonzalez will present on optimizing immunotherapy engagement at #Tandem25. Learn more in her recent Journal article on immunosuppression pharmacokinetics in patients with chronic #GVHD.

Attending #Tandem25? Dr. John Galvin will be presenting a session titled “Providing Novel Therapies to the World: International Considerations in Access and Regulatory Approval”. Read more about this topic in his recently published Journal article:

A study on behalf of the Acute Leukemia Working Party of @TheEBMT shows that the choice of TKI (imatinib or dasatnib) has no impact on survival after #alloHCT in Ph+ ALL. However, pre-transplant dasatinib may result in increased risk of severe acute GVHD.

A combination of anti-thymocyte globulin with post-transplant cyclophosphamide (ATG/PTCy) in an adjusted dosage for #GVHD prevention in haplo-HSCT is associated with a significantly lower risk of grades II-IV acute GVHD compared with ATG or PTCy alone.

Dr. Madiha Iqbal will discuss #HCT and cellular therapies in follicular lymphoma at #Tandem25. Read more about this topic in her article, published in the May 2023 issue of the Journal.

A study highlights gastric vascular ectasia (GVE) as a cause of upper GI bleeding post-allogeneic #HSCT, linked to sirolimus and PTCy-based #GVHD prophylaxis. While GVE presents significant morbidity, it often resolves with conservative management.

Dr. Michael Keller will present updates and best evidence for virus-specific T cells at #Tandem25. Read more about this topic in his article, published in the May 2023 issue of the journal.

A retrospective study of 115 patients with newly diagnosed multiple myeloma with del(17p) undergoing upfront auto-HCT found improved progression-free survival in those achieving MRD-negative CR post-transplant and receiving maintenance therapy. Read more:

Dr. Mazyar Shadman will discuss real-world outcomes of CD19 #CARTCell therapy in patients with primary mediastinal B-Cell lymphoma at #Tandem25. Read more about this topic in his article, published in the February 2023 issue of the journal.

This pilot study shows UM171-expanded cord blood grafts in tandem auto/allo #HCT for high risk myeloma patients are feasible, showing low chronic #GVHD rates and promising outcomes. Read more:

Modern bone marrow harvesting generally carries a minimal risk of contamination. This study finds that male sex is an independent risk factor for bone marrow harvests contamination. Further research is needed. Read more:

This cross-sectional Latin-American Bone Marrow Transplantation Group study reveals key gaps in hematopoietic cell transplantation (#HCT) training across Latin America, citing barriers like funding and procedure volume. Read the full analysis:

New research highlights the predictive power of the EASIX score after post-transplant cyclophosphamide (#PTCy). This study shows how the EASIX-HTN model stratifies #alloHCT patients by risk, offering NRM prediction. Read more:

New insights on #GVHD treatment demonstrate that serial monitoring of clinical response and biomarkers by day 14 can identify distinct risk groups, including an ultra-low risk group with exceptional outcomes. Read more:

The January issue of 'Transplantation and Cellular Therapy,' is now available online: @ELShematology

What influences revaccination in #HCT survivors? This survey found 62% of survivors were fully revaccinated, 33% partially and 4% had not received any revaccinations.. Factors include immune recovery, time since HCT and childhood vaccination history.

A national ASTCT survey of transplant and cellular therapy(TCT) advanced practice providers (APPs) reveals broad clinical roles, including biopsies and cellular infusions, but uncovers dissatisfaction with pay and work-life balance. Read more: